In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF)

Annals of Hematology

Volumn 81, Issue 12, 2002, Pages 695-700

  Faulhaber, Marion ^a   Wormann B ^b   Ganser, A ^a   Verbeek, W ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

Cytokines; Megakaryocytopoiesis; MGDF; Myelodysplastic; Thrombopoietin

Indexed keywords

CD61 ANTIGEN; DYE; ERYTHROPOIETIN; INTERLEUKIN 3; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PROPIDIUM IODIDE; STEM CELL FACTOR;

ARTICLE; BONE MARROW CELL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; LIQUID CULTURE; MEGAKARYOPOIESIS; MITOSIS; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; POLYPLOIDY; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEGAKARYOCYTES; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 0036958927     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0540-x     Document Type: Article

References (36)

1. Archimbaud E, Ottman O, Liu Yin J A et al. (1996) A randomized, double-blind, placebo-controlled, study using PEG-rhuMGDF as an adjunct to chemotherapy for adults with de-novo acute leukemia: Early results. Blood 88 [Suppl 1]:447a
2. Asano H, Hotta T, Ichihara M, Murate T, Kobayashi M, Saito H (1994) Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes. Leukemia 8:833-838
3. Basser R, Rasko JEJ, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG (1996) Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348:1279-1281
4. Bennett JM, Catovsky D, Flandrin G, Galton DAG, Gralnick HR, Sultan C, The French-American-British (FAB) Cooperative Group (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199
5. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca D, Scarlata D, Glaspy J (1997) Safety and biologic effect of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologeous peripheral blood progenitor cell transplantation. Blood 90 [Suppl 1]:171a
6. De Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang W-J, Oles KJ, Hultgren B, Solberg LA, Goeddel DV, Eaton DL (1994): Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand. Nature 369:533-538
7. Dower WJ, Cwirla SE, Balasubramanian P, Schatz PJ, Baccanaria DP, Barrett RW (1998) Peptide agonists of the thrombopoietin receptor. Stem Cells 16 [Suppl 2]: 21-29
8. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. New Engl J Med 336:404-409
9. Ganser A (1995) Hematopoietic factors in the treatment of the myelodysplastic syndromes. Curr Opin Hematol 2:204-209
10. Ganser A, Hoelzer D (1992) Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:607-618
11. Ganser A, Hoelzer D (1996) Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Semin Hematol 33:186-195
12. Ganser A, Karthaus M (1997) Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Leuk Lymphoma 26 [Suppl 1]:13-27
13. Geissler K, Kabrna E, Stengg S, Schwarzinger I, Knöbl P, Valent P, Eichinger S, Barge A, Lechner K (1997) Recombinant human megakaryocyte growth and development factor augments mobilization of hematopoietic progenitor cells post chemotherapy in patients with acute myeloid leukemia. Blood 90 [Suppl 1]:98a
14. Glaspy J, Vredenburgh J, Demetri GD, Chap L, Gilbert C, Overmoyer B, Warren DL, Berg R, Scarlata D, Menchaca D, Bolwell B (1997) Effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell transplantation (PBPC). Blood 90 [Suppl 1]:580a
15. Hellström-Lindberg E (2001) Treating the anemia of MDS with erythropoietin+G-CSF. Leuk Res 25 [Suppl 1]:8
16. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Öst A, Greenberg P (1997) Erythroid response to treatment with G-CSF plus erythropoietin for anemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344-351
17. Hofmann WK, Kalina U, Wagner S, Seipelt G, Ries C, Hoelzer D, Ottmann OG (1999) Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Exp Hematol 27:395-400
18. Jacobs A (1985) Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications. J Clin Pathol 38:1201-1217
19. Kalina U, Hofmann W, Koschmieder S, Wagner S, Kauschat D, Hoelzer D, Ottmann OG (2000) Alteration of c-mpl-mediated signal transduction in CD 34(+) cells from patients with myelodysplastic syndromes. Exp Hematol 28:1158-1163
20. Kaushansky K (1998) Thrombopoietin. New Engl J Med 339:746-754
21. Kirk SRE (1968) Experimental design procedures for the behavioral sciences. Brooks/Cole, Belmont
22. Kuter D, McCullough J, Romo, J, DiPersio J, Peterson R, Armstrong S, Menchaca D, Tomita D, Goodnough LT (1997) Treatment of platelet (PLT) donors with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increases circulating PLT counts (CTS) and PLT apheresis yields and increases platelet increments in recipients of PLT transfusions. Blood 90 [Suppl 1]:579a
23. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkhard D, Ching AFT, Mathews SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, ÓHara PJ, Hagen FS, Roth GJ, Foster DC (1994) Cloning and expression of murine thrombopoietin c DNA and stimulation of platelet production in vivo. Nature 369:565-568
24. McNiece IK, Langley KE, Zsebo KM (1991) Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 19:158-164
25. Merchav S, Nielsen OJ, Rosenbaum H, Sharon R, Brenner B, Tatarsky I, Scigalla P, Wieezorek L (1990) In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes. Leukemia 4:771-774
26. Metcalf D (1994) Blood. Thrombopoietin - at last. Nature 369:519-520
27. Moskowitz C, Nimer S, Gabrilove J et al. (1998) A randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety study of PEG-rHuMGDF (M) in non-Hodgkin's lymphoma(NHL) patients (pts) treated with ICE (ifosphamide, carboplatin and etoposide). Proc Am Soc Clin Oncol 17:76a
28. Rasko JEJ, Basser RL, Boyd J, Mansfield R, ÓMalley CJ, Hussein S, Berndt MC, Clarke K, ÓByrne J, Sheridan WP, Grigg AP, Begley CG (1997) Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br J Haematol 97:871-880
29. Schouten HC, Delwel R, Bot FJ, Hagemeijer A, Touw IP, Lowenberg B (1989) Characterization of clonogenic cells in refractory anemia with excess of blasts (RAEB-CFU): response to recombinant hematopoietic growth factors and maturation phenotypes. Leuk Res 13:245-251
30. Tehranchi R, Schmidt-Mende J, Forsblom L, Fadeel B, Zhivotovsky B, Heliström-Lindberg E (2001) FAS-triggered caspase activity is increased in sideroblastic anemia. Leuk Res 25 [Suppl 1]:59
31. Vadhan-Raj S, Verschraegen C, McGarry L, Bueso-Ramos C, Kudelka A, Freedman R, Edwards C, Bevers M, Levenback C, Gershenson D, Jones D, Yang T, Bast RC, Kavanagh J (1997) Recombinant human thrombopoietin (rhTPO) attenuates highdose carboplatin (C)-induced thrombocytopenia in patients with gynecologic malignancy. Blood 90 [Suppl 1]:580a
32. Verbeek W, Vehmeyer K, Wörmann B, Hiddemann W (1995) The effect of stem-cell factor, interleukin-3 and erythropoietin on in vitro erythropoiesis in myelodysplastic syndromes. J Cancer Res Clin Oncol 121:338-342
33. Visani G, Tosi P, Finelli C, Gamberi B, Zauli G, Cenacchi A, Fogli M, Colombini R, Tura S (1992) Effect of in vitro growth of haematopoietic progenitors in patients with myelodysplastic syndromes. Haematologica 77:142-145
34. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W (1994) c-Mpl ligand is a humoral regulator of megakaryopoiesis. Nature 369:571-574
35. Wolff SN, Herzig R, Lynch J, Ericson SG, Greer JP, Stein R, Goodman S, Benyunes MC, Ashby M, Jones DV, Fay J (2001) Recombinant human thrombopoietin after autologeous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study. Bone Marrow Transplant 27:261-268
36. Yoshida Y, Hirashima K, Asano S, Takaku F (1991) A phase I/II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78:378-384